2Mendis S, Thygesen K, Kuulasmaa K. World Health Organization definition of myocardial infarction :2008 - 09 revision [ J ]. Int J Epide- miol,2010, Oct :5.
3Erem Y, Eghiazarians Y, JOEL B, et al. The New England Journal of Medicine [ J ], 2000, 342:101 - 114.
4Sasisekharan R, Venkataraman G, Shriver Z.Methods and products related to low molecular weight heparin [ J 1. Patent Application Publi- cation,2010,11 : 1 - 30.
5Canales JF, Ferguson JJ. Low - molecular - weight heparins: mechanisms, trials, and role in contemporary interventional medicine [ J ]. Am J Cardiovasc Drugs ,2008,8 ( 1 ) : 15 - 25.
7Zeymer U, Gitt A, Jtlnger C, et al. Efficacy and safety of enoxaparin in unselected patients with ST- segment elevation myocardial infarction [ J ]. Thromb Haemost, 2008,99 ( 1 ) : 150 - 154.
8Zeymer U, Gitt A, Jtinger C, et al. Clinical benefit of enoxaparin in patients with high - risk acute coronary syndromes without ST ele- vations in clinical practice [ J ]. Am J Cardiol, 2006,98( 1 ) :19 -22.
6Rocha E, Imberti D, Paschina E. Low - molecular - weight Heparins:before or after surgery. Clin Drug Investing,2007, 27:357 - 366.
7Strebel N, Prins M, Agnelli G, et al. Preoperative or postoperative start of prophylaxis for venous thromboembolism with low- molecular- weight heparin in elective hip surgery. Arch Intern Med,2002,162 : 1451 - 1456.
